CFDE Data Portal | Search PFKP-DT

	Label	Description
	PFKP-DT Gene (Entity type)	ENSG00000273001 - PFKP divergent transcript
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS

PFKP-DT

ENSG00000273001 - PFKP divergent transcript

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.